Miguel Perales MD
@drmiguelperales.bsky.social
Chief Adult BMT MSKCC | Past-President ASTCT | Board Member NMDP | Chair Committee Transplant/Cell Ther ALLIANCE | Immigrant 🇪🇸🇬🇧 #MedSky Opinions mine/not MSK
https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
Pinned
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
Reposted by Miguel Perales MD
Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e
October 20, 2025 at 4:01 PM
Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e
Reposted by Miguel Perales MD
Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings.
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
October 23, 2025 at 6:30 PM
Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings.
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Reposted by Miguel Perales MD
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG
November 23, 2025 at 2:00 PM
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG
Reposted by Miguel Perales MD
For 40+ years, the ASH Scholar Award has helped jumpstart careers in hematology—funding 678 awards, $82M in research, and $3B in follow-on funding. Learn more: https://bit.ly/4idJLvV
#ASHAwards
#ASHAwards
November 20, 2025 at 8:00 PM
For 40+ years, the ASH Scholar Award has helped jumpstart careers in hematology—funding 678 awards, $82M in research, and $3B in follow-on funding. Learn more: https://bit.ly/4idJLvV
#ASHAwards
#ASHAwards
Reposted by Miguel Perales MD
Explore everything #ASH25 has to offer beyond the program!
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
November 21, 2025 at 3:05 PM
Explore everything #ASH25 has to offer beyond the program!
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
Reposted by Miguel Perales MD
Last chance to submit your comment! Public comments for draft recommendations for myelofibrosis close on November 24.
Learn more: https://ow.ly/ukja50Xf62F
Learn more: https://ow.ly/ukja50Xf62F
November 21, 2025 at 7:00 PM
Last chance to submit your comment! Public comments for draft recommendations for myelofibrosis close on November 24.
Learn more: https://ow.ly/ukja50Xf62F
Learn more: https://ow.ly/ukja50Xf62F
Reposted by Miguel Perales MD
Join Dr. Sewaralthahab to explore the classical hematology sessions sure to have a full house — including a guidelines session, abstract presentation, and Education Program session.
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
November 22, 2025 at 12:45 PM
Join Dr. Sewaralthahab to explore the classical hematology sessions sure to have a full house — including a guidelines session, abstract presentation, and Education Program session.
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
Reposted by Miguel Perales MD
Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
November 22, 2025 at 12:45 PM
Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
Reposted by Miguel Perales MD
📰 Your official #ASH25 news is here! The preview issue of #ASHNewsDaily is now live, with teasers of some can’t-miss sessions. 🧵
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
November 22, 2025 at 12:45 PM
📰 Your official #ASH25 news is here! The preview issue of #ASHNewsDaily is now live, with teasers of some can’t-miss sessions. 🧵
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines
www.nytimes.com
November 22, 2025 at 1:19 PM
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...
Reposted by Miguel Perales MD
Discussion of FDAs new super-rapid review process and criteria to get such rapid reviews. www.statnews.com/2025/11/21/f... via @statnews.com
The Trump administration is turning drug review into make-a-deal
“FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts warn.
www.statnews.com
November 21, 2025 at 1:08 PM
Discussion of FDAs new super-rapid review process and criteria to get such rapid reviews. www.statnews.com/2025/11/21/f... via @statnews.com
F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...
F.D.A. Names Agency Veteran to Run Drug Division
www.nytimes.com
November 12, 2025 at 12:24 PM
F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...
Reposted by Miguel Perales MD
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
Artificial intelligence in hematology
In the last 2 years, the capabilities of artificial intelligence (AI) have progressed rapidly and are increasingly being integrated into hematology practic
ashpublications.org
November 6, 2025 at 10:55 PM
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
Hopefully on my way to Alliance meeting in Chicago- look forward to Transplant and Cellular Based Therapies Committee tomorrow
November 6, 2025 at 9:15 PM
Hopefully on my way to Alliance meeting in Chicago- look forward to Transplant and Cellular Based Therapies Committee tomorrow
Reposted by Miguel Perales MD
A team at MSK is shedding new light on #VEXAS syndrome, a severe autoinflammatory condition arising from a mutation in the UBA1 gene.
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
November 6, 2025 at 6:39 PM
A team at MSK is shedding new light on #VEXAS syndrome, a severe autoinflammatory condition arising from a mutation in the UBA1 gene.
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say www.nytimes.com/2025/11/01/u...
‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say
www.nytimes.com
November 1, 2025 at 11:35 PM
‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say www.nytimes.com/2025/11/01/u...
Great meeting with friends and colleagues to discuss chronic GVHD last week in Detroit with Steven Pavletic, Daniel Couriel, Corey Cutler, Stephanie Lee & Stefanie Sarantopoulos
October 25, 2025 at 3:44 PM
Great meeting with friends and colleagues to discuss chronic GVHD last week in Detroit with Steven Pavletic, Daniel Couriel, Corey Cutler, Stephanie Lee & Stefanie Sarantopoulos
Reposted by Miguel Perales MD
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:
ESMO 2025 Research Roundup: MSK Presents Exciting Advances in Medical Oncology Research
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative...
www.mskcc.org
October 20, 2025 at 6:07 PM
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:
Reposted by Miguel Perales MD
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
October 18, 2025 at 5:02 PM
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
Reposted by Miguel Perales MD
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
October 18, 2025 at 12:57 PM
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
Reposted by Miguel Perales MD
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
October 18, 2025 at 3:02 PM
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
Reposted by Miguel Perales MD
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
October 17, 2025 at 5:03 PM
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
Reposted by Miguel Perales MD
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
October 10, 2025 at 9:37 AM
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
Reposted by Miguel Perales MD
Since 2012, the ASH Bridge Grant has funded 205 researchers with $28M, leading to $680M in follow-on NIH funding. These grants keep labs running and fuel breakthroughs in hematology. Learn more: https://bit.ly/48yINrB
October 10, 2025 at 8:01 PM
Since 2012, the ASH Bridge Grant has funded 205 researchers with $28M, leading to $680M in follow-on NIH funding. These grants keep labs running and fuel breakthroughs in hematology. Learn more: https://bit.ly/48yINrB
Reposted by Miguel Perales MD
At 7 years old, Emily became the first child in the world to receive CAR T-cell therapy. After three relapses and being sent to hospice, Emily got a second chance at life with this treatment. Help protect access to life-saving treatments: https://ow.ly/rXY150X5Tso
#Fight4Hematology #HemeSky
#Fight4Hematology #HemeSky
October 10, 2025 at 2:01 PM
At 7 years old, Emily became the first child in the world to receive CAR T-cell therapy. After three relapses and being sent to hospice, Emily got a second chance at life with this treatment. Help protect access to life-saving treatments: https://ow.ly/rXY150X5Tso
#Fight4Hematology #HemeSky
#Fight4Hematology #HemeSky